0
Letters |

Relationship Between Hormone Replacement Therapy, Socioeconomic Status, and Coronary Heart DiseaseRelationship Between Hormone Replacement Therapy, Socioeconomic Status, and Coronary Heart Disease

JAMA. 2003;289(1):44-45. doi:10.1001/jama.289.1.44
Text Size: A A A
Published online

AUTHOR INFORMATION

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

RELATIONSHIP BETWEEN HORMONE REPLACEMENT THERAPY, SOCIOECONOMIC STATUS, AND CORONARY HEART DISEASE

To the Editor: In their review of observational studies of postmenopausal hormone replacement therapy (HRT), Dr Nelson and colleagues1 incorrectly claim that our findings from the Nurses' Health Study (NHS)2 3 failed to control for education or socioeconomic status (SES) in analyzing postmenopausal HRT use and risk of coronary heart disease (CHD). Because all NHS participants are registered nurses, with nearly identical education, we adjusted for education using stratification.2 3 The authors also incorrectly state that studies controlling for alcohol intake or physical activity failed to observe a lower risk of CHD among HRT users. We recently reported a relative risk (RR) of CHD of 0.64 (95% confidence interval, 0.54-0.76) for current vs never HRT users, after adjustment for alcohol and physical activity (in addition to other covariates).2

Nelson et al cited 4 studies that controlled for SES and yielded nonsignificant results for risk of CHD. However, these studies do not support the contention that control for SES explains these results. Sidney et al4 stated that adjustment of their results for education resulted in minimal changes in the RR estimate of CHD risk, from 0.92 to 0.96. Rosenberg et al5 stated that adjustment for factors other than age at and type of menopause had little impact on their RR estimates for CHD. Croft and Hannaford6 reported an unadjusted RR of 0.8 for HRT use and CHD risk, which was entirely unchanged after adjustment for social class (and other covariates). Thus, it is clear from these study results that adjustment for education did not affect results for CHD risk.

Finally, Nelson et al only presented separate meta-analyses by SES adjustment for CHD, although most of the other diseases examined also are strongly associated with SES. If confounding by SES were truly the explanation for the CHD results, it is unlikely that such confounding would not be crucial for other diseases as well. Indeed, the NHS and other observational studies yielded RRs for osteoporotic fracture, breast cancer, colon cancer, venous thromboembolism, and stroke nearly identical to the results of the Women's Health Initiative,7 suggesting a lack of important confounding. Moreover, the Women's Health Initiative trial addressed a different issue than the observational studies; that is, postmenopausal women using continuous combined HRT initiated many years after the onset of menopause. This difference may be particularly important for the outcome of heart disease. Mikkola and Clarkson8 demonstrated in trials of monkeys that HRT begun only at the onset of menopause showed cardiovascular protection. The sparse data available in humans suggest a similar phenomenon. We believe that biologically based hypotheses are more likely to explain the apparent divergence in findings for CHD than the supposed confounding by SES.

References
Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review.  JAMA.2002;288:872-881.
Grodstein F, Manson JE, Colditz GA, Willet WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.  Ann Intern Med.2000;133:933-941.
Grodstein F, Stampfer MJ, Janson JE.  et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease.  N Engl J Med.1996;335:453-461. [published correction appears in N Engl J Med. 1996;335:1406].
Sidney S, Petitti DB, Quesenberry Jr CP. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women.  Ann Intern Med.1997;127:501-508.
Rosenberg L, Palmer JR, Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements.  Am J Epidemiol.1993;137:54-63.
Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study.  BMJ.1989;298:165-168.
Women's Health Initiative Investigators.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women.  JAMA.2002;288:321-333.
Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function.  Cardiovasc Res.2002;53:605-619.

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review.  JAMA.2002;288:872-881.
Grodstein F, Manson JE, Colditz GA, Willet WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.  Ann Intern Med.2000;133:933-941.
Grodstein F, Stampfer MJ, Janson JE.  et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease.  N Engl J Med.1996;335:453-461. [published correction appears in N Engl J Med. 1996;335:1406].
Sidney S, Petitti DB, Quesenberry Jr CP. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women.  Ann Intern Med.1997;127:501-508.
Rosenberg L, Palmer JR, Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements.  Am J Epidemiol.1993;137:54-63.
Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study.  BMJ.1989;298:165-168.
Women's Health Initiative Investigators.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women.  JAMA.2002;288:321-333.
Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function.  Cardiovasc Res.2002;53:605-619.
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.